Patritumab Deruxtecan (HER3-DXd)
CAS: 2227102-46-5
Description:
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) designed to target HER3, a protein found on many tumor cells. It combines an anti-HER3 monoclonal antibody, patritumab, with deruxtecan (DXd), a chemotherapy drug that targets DNA. The antibody binds to HER3 on cancer cells, delivering deruxtecan directly to the tumor, where it causes DNA damage and cell death. This ADC is being studied for treating HER3-positive cancers like non-small cell lung cancer (NSCLC) and breast cancer.
Key Features:
- HER3 Targeting: Specifically binds to HER3 on tumor cells, ensuring the drug reaches its target.
- Cytotoxic Agent (Deruxtecan/DXd): Deruxtecan is a DNA-alkylating agent that disrupts DNA replication, killing cancer cells.
- Linker Technology: The stable linker connects the antibody to deruxtecan, releasing the drug inside cancer cells.
Applications:
- Cancer Treatment: Targets and destroys HER3-positive cancer cells, particularly in NSCLC, breast cancer, and other solid tumors.
- Targeted Therapy: Delivers deruxtecan directly to the cancer, minimizing damage to healthy tissue.
- Monoclonal Antibody Therapy: Provides an effective treatment for tumors expressing HER3, offering a precise approach to chemotherapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.